

4539



Structure-function studies on human granulocyte-macrophage colony-stimulating factor

Timothy Robert Hercus, B.Sc. (Hons.)

**A thesis submitted for the degree of Doctor of Philosophy of the
University of Adelaide (Faculty of Science)**

**Division of Human Immunology
Institute of Medical and Veterinary Science
Department of Microbiology and Immunology
University of Adelaide
Adelaide, South Australia**

August 1994

Awarded 1995

Contents

Summary	i
Declaration	iv
Acknowledgments	v
Chapter 1 Introduction	
1.1 Haemopoiesis and the colony stimulating factors	1
1.2 Granulocyte-macrophage colony-stimulating factor	2
1.3 Project aims	9
Chapter 2 Materials and Methods	
2.1 Abbreviations	10
2.2 Chemicals, reagents and consumables	12
2.3 Radiochemicals and radiolabelled reagents	14
2.4 Enzymes	14
2.5 Bacterial strains and genotypes	15
2.6 Cloning and expression vectors	16
2.7 Cloned DNA sequences	16
2.8 Standard solutions and bacterial media	17
2.9 Molecular weight standards	18
2.10 Methods	19
2.10.1 Processing oligonucleotides	19
2.10.2 The polymerase chain reaction	22
2.10.3 Maintenance and transformation of <i>E. coli</i>	22
2.10.4 M13 mutagenesis protocol	25
2.10.5 Preparation of M13 and plasmid DNA	27
2.10.6 DNA sequencing	30
2.10.7 Transfection of COS and CHO cells	32
2.10.8 Osmotic shock protocol	33
2.10.9 Preparation and use of immunoaffinity columns	34

2.10.10	Radioiodination of recombinant cytokines	36
2.10.11	Quantification of GM-CSF	36
2.10.12	Electrophoresis of proteins	37
2.10.13	Visualisation of proteins after electrophoresis	40
2.10.14	Protein sequencing	42
2.10.15	Purification of neutrophils and monocytes	43
2.10.16	GM-CSF biological activity assays	44
2.10.17	GM-CSF receptor binding assays	46

Chapter 3 Structure-function studies on human GM-CSF: Identification of two potential receptor binding sites

3.1	Introduction	49
3.1.1	Hydropathy analysis of human GM-CSF	50
3.2	Methods	51
3.2.1	Protocol for the identification of functionally important regions of GM-CSF	51
3.2	Results	52
3.3.1	Analysis of residues in the predicted first α -helix of GM-CSF	52
3.3.2	Analysis of residues in the predicted fourth α -helix of GM-CSF	58
3.3.3	Mutagenesis of the disulphide-bonded cysteine residues of GM-CSF	60
3.4	Discussion	62
3.4.1	Identification of functionally important residues in human GM-CSF	62
3.4.2	The structure of human GM-CSF	65
3.4.3	A model for the interaction of GM-CSF with the two chains of the GM-CSF receptor complex	67

Chapter 4 Saturation mutagenesis of residues in the first α -helix of GM-CSF

4.1	Introduction	69
4.2	Results	70
4.2.1	A potential problem for site-directed mutagenesis in the first α -helix of GM-CSF	70
4.2.2	A more efficient mutagenesis protocol, OCM	71

4.2.3	Preparation of plasmid constructs for OCM of the first α -helix of GM-CSF	72
4.2.4	OCM of the first α -helix of GM-CSF	73
4.2.5	The biological activity of GM-CSF mutants	74
4.2.6	The binding of GM-CSF mutants to the low (α) and high ($\alpha\beta_c$) affinity GM-CSF receptors	75
4.3	Discussion	76

Chapter 5 The expression and purification of GM-CSF residue 21 analogues from an *E. coli* secretion system

5.1	Introduction	80
5.1.1	Expression of heterologous proteins in <i>E. coli</i>	81
5.2	Results	83
5.2.1	Mutagenesis of pshGM-CSF	84
5.2.2	Expression of wild type GM-CSF and analogues	86
5.2.3	Improving the expression of the E21R analogue	87
5.2.4	Purification of GM-CSF	89
5.2.3	Quantification of purified GM-CSF	95
5.3	Discussion	97

Chapter 6 The biological activities and receptor binding properties of *E. coli*-derived residue 21 analogues: Identification of GM-CSF antagonists

6.1	Introduction	101
6.2	Results	102
6.2.1	Activity of <i>E. coli</i> -derived wild type GM-CSF	102
6.2.2	Comparison of the activity of eco GM-CSF and eco E21R	103
6.2.3	Receptor binding characteristics of eco E21R	104
6.2.4	Comparison of eco E21R and cho E21R	105
6.2.5	Analysis of eco E21R for antagonism of GM-CSF mediated proliferation	108
6.2.6	Eco E21R antagonism of neutrophil activation	109
6.2.7	Activity of multiple residue 21 analogues	110
6.2.8	Analysis of eco E21K for antagonistic activity	111
6.3	Discussion	112
6.3.1	The properties of GM-CSF residue 21 analogues	112

6.3.2	Potential role of carbohydrate in cho E21R	115
6.3.3	Clinical relevance of GM-CSF antagonists	117
Chapter 7 Final Discussion		119
Appendices		
Bibliography		vii
Publications		

Summary

The aim of the work described in this thesis was to study the structure-function properties of the human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF) in order to generate molecules with novel biological properties. The approach used was to generate mutated forms of GM-CSF cDNA, express mutant proteins and examine their biological activity and receptor binding properties.

At the time the work for this thesis commenced the structure of GM-CSF had not yet been determined. However, the predicted structure of GM-CSF was a bundle of four alpha helices containing hydrophilic regions. Initial studies using COS and CHO cell expression systems focussed on residues within the first predicted helix of GM-CSF that contribute to a prominent hydrophilic peak. Deletion analysis and substitution mutagenesis of residues 20 and 21 indicated that Glu²¹ was a functionally significant residue as charge reversal mutations at this position reduced GM-CSF activity 300-fold. A variety of amino acid substitutions at position 21 indicated a hierarchy of tolerance with Glu,Asp > Asn > Ala > Ser > Gln > Lys,Arg. The results indicated that Glu²¹ was essential for multiple GM-CSF activities including cell proliferation and mature cell activation.

The GM-CSF receptor comprises a GM-CSF specific, low affinity receptor α chain (GMR α) and a β chain (β_c) that does not by itself detectably bind GM-CSF but confers high affinity binding when co-expressed with the α chain and is required for signal transduction. The β_c chain is shared with the IL-3 and IL-5 receptors. Receptor binding studies with residue 21 analogues indicated that Glu²¹ is essential for binding to the high affinity (GMR $\alpha\beta_c$) but not the low affinity (GMR α) receptor. The results identified the presence of two functional domains of GM-CSF required for either GMR α

or GMR α β_c interaction and demonstrated that GM-CSF stimulation of both proliferation and mature cell activation are mediated through high affinity receptors.

The functional role of other residues in the first alpha helix was examined in light of the critical role determined for Glu²¹. Oligonucleotide cassette mutagenesis (OCM) was developed to generate large numbers of mutants for expression in COS cells. Residues 14 and 17 to 28 of the first alpha helix of human GM-CSF were subjected to extensive substitution mutagenesis. Mutation of most amino acids buried in the hydrophobic core did not significantly impair biological activity or receptor binding apart from a modest decrease in biological activity observed with mutation of residues Ala²² and Leu²⁶. Mutation of Ile¹⁹ produced a marked decrease in biological activity and receptor binding, probably as a result of structural perturbations. Mutation of amino acids located on the surface of the first helix did not significantly impair biological activity or receptor binding, with the notable exception of Glu²¹ (discussed above). The conclusion was that residue 21 is the only significant β_c chain contact on the surface of the first helix.

The carboxy terminus of GM-CSF contains a prominent hydrophilic peak centred over the fourth alpha helix with a number of charged amino acids conserved across several species. The importance of these residues was examined by charge reversal mutagenesis and indicated a role in GM-CSF biological activity for Asp¹¹². Binding studies showed a reduction in high- and low-affinity binding for the D112R analogue. In this respect residue 112 appears to be functionally distinct from residue 21 and is apparently involved in binding to the GMR α chain.

An *E. coli* expression system was used to produce larger quantities of GM-CSF residue 21 analogues for detailed receptor binding studies and to enable structural characterisation. The analogues which included hydrophobic (Ala, Phe), hydrophilic (Gln) and basic (His, Lys, Arg) substitutions at position 21, proved refractive to expression but techniques were devised that enabled their expression and purification.

The *E. coli*-derived GM-CSF residue 21 analogues displayed a range of biological activities, yet they all exhibited low affinity binding characteristics on both GMR α and GMR $\alpha\beta_c$, similar to CHO cell-derived analogues. The E21R and E21K charge reversal analogues, were surprisingly devoid of activity. The lack of activity from the *E. coli*-derived E21R analogue was in marked contrast to the activity observed for the CHO cell-derived E21R analogue. These results demonstrated that although in some cases low affinity binding can lead to biological signalling, in other cases such as with the E21R and E21K analogues, low affinity binding can be dissociated from receptor activation and biological signalling.

The *E. coli*-derived E21R and E21K analogues, which bind GMR α chain without eliciting a functional response, were tested for antagonistic activity. Both analogues were effective antagonists of the GM-CSF-mediated proliferation of leukaemic cells and the GM-CSF-mediated release of superoxide anions from neutrophils. The antagonism was effective against glycosylated and non-glycosylated forms of GM-CSF and was specific for GM-CSF in that no antagonism of IL-3-mediated leukaemic cell proliferation or TNF- α -mediated neutrophil superoxide production was observed.

On the basis of the observations presented in this thesis, a model for the interaction of GM-CSF with the receptor complex is proposed that should also be applicable to related cytokines, IL-3 and IL-5 in particular. The critical feature of this model is that GM-CSF contains two functionally distinct receptor binding sites, one for the GMR α chain and another for the β_c chain. The GMR α chain binding site includes residues from the fourth helix and in particular the Asp¹¹² residue. The β_c chain binding site includes only Glu²¹ of the first helix. A model to account for the antagonism of GM-CSF activity is presented which proposes that the antagonist sequesters the available GMR α chain into complexes unable to associate with the β_c chain and therefore prevents wild type GM-CSF interaction with the GM-CSF receptor complex. Possible clinical implications for GM-CSF antagonists are discussed.